Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Earnings Results, Misses Estimates By $0.14 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) posted its quarterly earnings data on Thursday. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14), FiscalAI reports. The company had revenue of $208.60 million during the quarter, compared to analyst estimates of $217.56 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%. Supernus Pharmaceuticals’s revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.80) earnings per share.

Here are the key takeaways from Supernus Pharmaceuticals’ conference call:

• Strong third-quarter performance: Revenue rose 18% year over year to a record $226.8 million, while GAAP net income reached $20.9 million versus a $45.1 million loss in the prior-year quarter.
• Management raised standalone 2026 guidance, now expecting total revenue of $875 million–$900 million and non-GAAP operating earnings of $160 million–$180 million.
• Growth products continued to gain momentum, with combined revenue from Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI up 43%; Qelbree prescriptions increased 18%, ZURZUVAE U.S. sales grew about 53%, and ONAPGO sales rose 27% sequentially.
• Supernus and Indivior shareholders approved the merger, with closing expected November 2. Management remains confident in achieving the projected $125 million in annual cost synergies and plans to issue combined 2027 guidance in February.
• SPN-820 and SPN-817 Phase IIb trials continue enrolling, while SPN-443 is expected to enter Phase I by year-end; SPN-817 epilepsy data may not be available until 2028 because recruitment is progressing slowly.

Supernus Pharmaceuticals Trading Up 1.9%

NASDAQ SUPN traded up $0.76 during trading hours on Thursday, hitting $41.84. 1,885,191 shares of the company’s stock were exchanged, compared to its average volume of 976,567. The stock has a 50-day simple moving average of $42.61 and a 200 day simple moving average of $47.37. Supernus Pharmaceuticals has a 1-year low of $37.54 and a 1-year high of $59.68. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -21.79, a PEG ratio of 1.21 and a beta of 0.55.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Finally, Cantor Fitzgerald lifted their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $62.33.

Key Stories Impacting Supernus Pharmaceuticals

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Adjusted earnings beat expectations: Supernus reported third-quarter adjusted earnings of $0.93 per share, well above the Zacks consensus estimate of $0.49. Although earnings declined from $1.01 a year earlier, the sizable estimate beat supports investor confidence in the company’s operating performance. Supernus Pharmaceuticals Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Sales growth and guidance were encouraging: Third-quarter revenue rose 18% year over year to $208.6 million, while management reportedly provided optimistic full-year sales guidance. Continued commercial momentum is a positive signal for future revenue and cash generation. Supernus Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Pipeline progress added a potential catalyst: Supernus advanced its Phase 2 SPN-821 depression study. Further clinical progress could expand the company’s growth opportunities beyond its existing CNS portfolio, though development and regulatory risks remain. Supernus Advances SPN-821 Depression Trial
• Neutral Sentiment: Reported earnings figures vary by measure: One report cited $0.35 in EPS versus a $0.49 consensus estimate, while the adjusted figure reported by Zacks was $0.93. Investors should verify the reconciliation between GAAP and adjusted results when assessing the quarter. Supernus Q3 2026 Earnings Call Transcript
• Negative Sentiment: Profitability remains a concern: The reported quarter included a negative net margin, and some published results showed EPS and revenue below consensus. These factors could limit the durability of the positive reaction if future results do not sustain the adjusted-earnings beat.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.